US 12,234,300 B2
Conjugated hepcidin mimetics
Gregory Thomas Bourne, Brisbane (AU); Ashok Bhandari, Pleasanton, CA (US); Brian Troy Frederick, Ben Lomand, CA (US); Jie Zhang, Salisbury (AU); Adam Stephenson, Chapel Hill (AU); Mark Leslie Smythe, Bardon (AU); Roopa Taranath, Cupertino, CA (US); and David Y. Liu, Newark, CA (US)
Assigned to Protagonist Therapeutics, Inc., Newark, CA (US)
Filed by Protagonist Therapeutics, Inc., Newark, CA (US)
Filed on Aug. 7, 2023, as Appl. No. 18/366,558.
Application 18/366,558 is a continuation of application No. 16/964,708, granted, now 11,753,443, previously published as PCT/US2019/017192, filed on Feb. 8, 2019.
Claims priority of provisional application 62/749,450, filed on Oct. 23, 2018.
Claims priority of provisional application 62/717,390, filed on Aug. 10, 2018.
Claims priority of provisional application 62/627,948, filed on Feb. 8, 2018.
Claims priority of provisional application 62/627,952, filed on Feb. 8, 2018.
Prior Publication US 2024/0209024 A1, Jun. 27, 2024
Int. Cl. C07K 7/08 (2006.01); A61K 9/00 (2006.01); A61K 38/00 (2006.01)
CPC C07K 7/08 (2013.01) [A61K 9/0053 (2013.01); A61K 38/00 (2013.01)] 18 Claims
 
1. A peptide or a peptide dimer thereof, wherein the peptide comprises or consists of:
(SEQ ID NO: 158)
Isovaleric acid-DTH-[Dpa]-PCI-[(D)Lys]-[b-hPhe]-
[Lys(IsoGlu-Palm)]-[(D)Lys]-C-NH2;
 
(SEQ ID NO: 159)
Isovaleric acid-DTH-[Dpa]-PCI-[(D)Lys-Ac]-
[b-hPhe]-[Lys(Peg11-Palm)]-[(D)Lys-Acl-C-NH2;
 
(SEQ ID NO: 165)
Isovaleric acid-DTH-[Dpa]-PCI-[(D)Lys]-[b-hPhe]-
[Lys(Ahx-Palm)]-[(D)Lys]-C-NH2;
 
(SEQ ID NO: 166)
Isovaleric acid-DTH-[Dpa]-PCI-[(D)Lys-(Peg11-
OMe)]-[b-hPhe]-[Lys(Ahx-Palm)]-[(D)Lys-  
(Peg11-OMe)]-C-NH2; or
 
(SEQ ID NO: 175)
Isovaleric_Acid-D-T-H-[Dpa]-P-C-I-(D)Lys-bhPhe-
[Lys_Peg11_Palm]-dLys_Ac-C-NH2,
wherein the peptide is cyclized via a disulfide bond between two cysteines.